Alexion reiterated at buy by Merrill

Alexion Pharmaceuticals Inc. was reiterated at buy by Merrill Lynch analyst David Munno after the company reported positive interim safety data from the open-label Shepherd study, which met its primary endpoint of reduction in intravascular hemolysis. Merrill believes Alexion will meet with the Food and Drug Administration in regards to submitting a Biologics License Application, based on the positive safety data. Shares of the Cheshire, Conn.-based biotechnology company were up 20 cents, or 0.62%, at $32.70 on volume of 468,253 shares versus the three-month running average of 355,346 shares. (Nasdaq: ALXN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.